Merck & Co. Calls Time On Flop TIGIT And LAG-3 Programs

After investing heavily in both mechanisms for IO-IO combinations, Merck is cutting its losses with vibostolimab and favezelimab, and switching its anticancer bets to other modalities.

(Shutterstock)

Once a key part of its next-generation plans in cancer, Merck & Co. has called a halt to the last remaining Phase III studies of its TIGIT- and LAG-3 targeting immunotherapy assets.

The two immunotherapy mechanisms had been seen as strong contenders for use in combination with anti-PD-1/L-1 checkpoint inhibitors, most notably...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from Anticancer